United States - English - NLM (National Library of Medicine)

alk-abello, inc. - dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p) - dactylis glomerata pollen 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

United States - English - NLM (National Library of Medicine)

stallergenes - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense top - unii:s7pw24bx20, phleum pratense pollen - unii:65m88rw2eg), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), lolium perenne pollen (unii: 4t81lb52r0) (lolium perenne pollen - unii:4t81lb52r0) - anthoxanthum odoratum pollen 100 [ir] - oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for any of the five grass species contained in this product. oralair is approved for use in persons 5 through 65 years of age. oralair is not indicated for the immediate relief of allergy symptoms. oralair is contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic allergic reaction - history of any severe local reaction to sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients (mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate and lactose monohydrate) contained in this product [ see description (11) ] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dactylis glomerata) pollen 100dbu/ml solution for skin prick test (lofarma - cocksfoot (orchard grass, dactylis glomerata) pollen allergen extract - solution for skin-prick test

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dactylis glomerata) pollen 5hep solution for skin prick test (diater - cocksfoot (orchard grass, dactylis glomerata) pollen allergen extract - solution for skin-prick test

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dactylis glomerata) pollen 50hep/ml solution for skin prick test (inmunotek - cocksfoot (orchard grass, dactylis glomerata) pollen allergen extract - solution for skin-prick test

United States - English - NLM (National Library of Medicine)

cenexi hsc - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense top - unii:s7pw24bx20, phleum pratense pollen - unii:65m88rw2eg), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), lolium perenne pollen (unii: 4t81lb52r0) (lolium perenne pollen - unii:4t81lb52r0) - oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for any of the five grass species contained in this product. oralair is approved for use in persons 5 through 65 years of age. oralair is not indicated for the immediate relief of allergy symptoms. oralair is contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic allergic reaction - history of any severe local reaction to sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients (mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate and lactose monohydrate) contained in this product [ see description (11) ] risk summary all pregnancies have a risk of birth defect, loss, or other a

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 1000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p) - dactylis glomerata pollen 10000 [bau] in 1 ml - standardized pollen extract is intended for use in the diagnosis and therapy of pollen allergic patients as established by allergy history and skin test reactivity. standardized grass pollen extracts labeled in bau/ml are not interchangeable with grass pollen extracts labeled in au/ml or with non-standardized grass pollen extracts. the 10,000 bau/ml dose form is indicated for percutaneous testing. if negative, 100,000 bau/ml dose form can be used for percutaneous testing. for immunotherapy, availability of 10,000 and 100,000 bau/ml dosages facilitates safe switching. (see dosage & administration) the use of standardized grass pollen extracts is indicated for hyposensitization treatment and may be used as part of the over-all management of the allergic patient. treatment of grass sensitive patients consists of using specific standardized grass products of up to and including doses of 100,000 bau/ml (up to 10,000 bau/ml for bermuda grass) or stock mixtures of standardized grass products. stock mixtures of s